Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open Label, Dose-Escalation Study to Determine the Safety, Tolerability and Efficacy of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor BMS-201038 in Patients With Homozygous Familial Hypercholeterolemia

NCT01556906 is registered in ClinicalTrials.gov with Aegerion Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01556906
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01556906 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open Label, Dose-Escalation Study to Determine the Safety, Tolerability and Efficacy of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor BMS-201038 in Patients With Homozygous Familial Hypercholeterolemia
Lead sponsor
Aegerion Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2003
Completion date
February 29, 2004
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

homozygous familial hypercholesterolemia